Actinogen Expected to Treat First Patient Within Weeks

Actinogen Medical (ASX: ACW) is pleased to provide a summary of its progress over the quarter ended 31 March 2017.

KEY TAKEAWAYS:

• Significant progress achieved with XanADu, Actinogen Medical’s Phase II clinical trial of Xanamem™ in Alzheimer’s disease.
• 17 of a total planned 20 trial sites globally have been selected, with four of these actively recruiting patients.
• Treatment of first patient expected to start within weeks.
• XanADu represents a landmark in the global search for an effective treatment for Alzheimer’s disease and reinforces Australia’s role at the forefront of Alzheimer’s disease research.
• Recruitment follows regulatory approval received for XanADu in the US, the UK and Australia during the quarter.
• Healthcare industry and venture capital veteran, Dr Geoff Brooke, appointed as Chairman.
• Cash at 31^st March 2017 of $5.2 million.

Actinogen Medical has made significant progress during the quarter with XanADu and expects to recruit the first patients for this landmark trial within weeks.

The Company remains focused on ensuring the trial progresses as expected and looks forward to updating the market on its progress over the near to medium term. Topline trial results are expected in early 2019.

“We have made excellent progress over the past few months with XanADu and expect to announce the successful recruitment of the first patient imminently. This ground breaking trial shows that Australia is leading the way in developing this promising new treatment for Alzheimer’s disease,” said Dr Bill Ketelbey, CEO of Actinogen Medical.

“The development of Xanamem could potentially be one of the most significant contributions Australian clinical development will make to the management of Alzheimer’s disease- a disease presenting as the next major global health challenge for which new treatments are desperately needed.”

Actinogen Medical (ASX:ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and  metabolic disease. Actinogen medical is developing Xanamem™ a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential.

Full Article

Request Information